In this edition, we look at the first FDA approval of an oral therapy for chronic spontaneous urticaria, and more.
Read the full coverage here:
FDA approves first oral therapy for chronic spontaneous urticaria
Denifanstat safe, effective in acne vulgaris treatment
FDA approves Zoryve cream 0.05% for pediatric atopic dermatitis
The 'Zoom boom' effect: Post-pandemic cost concerns for facial cosmetic procedures
References:
F Xiang, et al. Abstract #LBA-213. Presented at: European Academy of Dermatology and Venereology Congress; Sept. 17-20, 2025; Paris.
Pecora V, et al. J Drugs Dermatol. 2025;doi:10.36849/JDD.9102.
Press Release
Press Release
